In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
As of close of business last night, GlycoMimetics Inc’s stock clocked out at $0.18, down -0.56% from its previous closing price of $0.18. In other words, the price has decreased by -$0.56 from its previous closing price. On the day, 0.92 million shares were traded. GLYC stock price reached its highest trading level at $0.183 during the session, while it also had its lowest trading level at $0.175.
Ratios:
To gain a deeper understanding of GLYC’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.48 and its Current Ratio is at 5.48. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.00.
On December 22, 2023, CapitalOne started tracking the stock assigning a Overweight rating and target price of $12.
Jefferies Upgraded its Hold to Buy on November 12, 2021, whereas the target price for the stock was revised from $3 to $4.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Aug 08 ’24 when Invus Public Equities, L.P. sold 260,873 shares for $0.19 per share. The transaction valued at 50,009 led to the insider holds 6,317,565 shares of the business.
Invus Public Equities, L.P. sold 61,488 shares of GLYC for $11,197 on Aug 07 ’24. The 10% Owner now owns 6,578,438 shares after completing the transaction at $0.18 per share. On Aug 05 ’24, another insider, Invus Public Equities, L.P., who serves as the 10% Owner of the company, sold 164,523 shares for $0.19 each. As a result, the insider received 30,996 and left with 6,695,658 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GLYC now has a Market Capitalization of 11491049 and an Enterprise Value of -10446236. For the stock, the TTM Price-to-Sale (P/S) ratio is 1149.03 while its Price-to-Book (P/B) ratio in mrq is 0.57. Its current Enterprise Value per Revenue stands at -1044.624 whereas that against EBITDA is 0.256.
Stock Price History:
Over the past 52 weeks, GLYC has reached a high of $3.53, while it has fallen to a 52-week low of $0.17. The 50-Day Moving Average of the stock is -30.07%, while the 200-Day Moving Average is calculated to be -89.12%.
Shares Statistics:
It appears that GLYC traded 3.77M shares on average per day over the past three months and 1178010 shares per day over the past ten days. A total of 64.39M shares are outstanding, with a floating share count of 62.49M. Insiders hold about 6.54% of the company’s shares, while institutions hold 35.58% stake in the company. Shares short for GLYC as of 1722384000 were 3114367 with a Short Ratio of 0.83, compared to 1719532800 on 5105772. Therefore, it implies a Short% of Shares Outstanding of 3114367 and a Short% of Float of 6.959999999999999.
Earnings Estimates
Its stock is currently analyzed by 4.0 different market analysts. The consensus estimate for the next quarter is -$0.11, with high estimates of -$0.07 and low estimates of -$0.16.
Analysts are recommending an EPS of between -$0.5 and -$0.75 for the fiscal current year, implying an average EPS of -$0.61. EPS for the following year is -$0.43, with 4.0 analysts recommending between -$0.08 and -$0.9.
